Evaluation of the effect of sodium valproate and Levetiracetam on the prevention of migraine headaches
Phase 2
Recruiting
- Conditions
- migraine.Migraine
- Registration Number
- IRCT20171030037093N14
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Age 18 to 65 years old
Migraine headache history for at least 6 months before study based on IHS criteria
Moderate to severe headache for less than 6 days with Visual Analogue Scale
Natural Signs and Natural Nerve Findings.
Exclusion Criteria
Patients with kidney failure, liver disease, heart disease, active stomach ulcer disease or diabetes or abnormal vital symptoms
Allergy to valproate and Levetiracetam
Pregnant or lactating women
Cases of other types of headaches such as sinus headaches
Taking nonsteroidal anti-inflammatory drugs within 24 hours or valproate over the past 2 weeks
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Headache severity. Timepoint: Before the start of the study, notes were taken every 30 days. Method of measurement: Based on VAS and doctor.;Number of headaches per month. Timepoint: Before the start of the study, notes were taken every 30 days. Method of measurement: MIDAS questionnaire.
- Secondary Outcome Measures
Name Time Method